A pilot study of gestational diabetes mellitus not controlled by diet alone: First-line medical treatment with myoinositol may limit the need for insulin

The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes

“…In the case of GDM, a condition defined as a glucose impairment first detected in pregnancy, a preventive role of inositol for GDM onset was recognized [12–14]. In addition, inositol has been studied as a therapeutic option for the treatment of GDM [15, 16]. The main effect of inositol when used in pregnancy is decreasing the level of insulin resistance.…”

Article Review: Coloration Biochemistry and Molecular Biology Between Polycystic Ovary Syndrome and Diabetes Mellitus Type 2

“…There was a significant LD between the SNPs of the genes on the same chromosome, "notably TCF7L2, IGF2BP2, CDKAL1, HHEX, and CAPN10", but no LD between the genes on the same chromosome, as anticipated [40][41][42][43][44][45] . Only nine SNPs from the nine genes were selected for the multivariate and interaction analyses based on the reported LD pattern, i.e.…”

A review of the role of inositols in conditions of insulin dysregulation and in uncomplicated and pathological pregnancy

“…This study found that insulin resistance was significantly decreased in women given myo-inositol, and that groups on myo-inositol-containing interventions (but not the chiroinositol alone group) were less likely to require insulin therapy, and delivered newborns with significantly lower birthweights. A third observational study also found that women with GDM treated with 1.2 g myo-inositol were less likely to require insulin treatment later in pregnancy but lacked a contemporaneous control group for valid comparison (Lubin et al 2016). Collectively, these studies suggest that myo-inositol could potentially be considered as first line GDM therapy, or as adjuvant therapy with insulin to reduce insulin dosage and reduce the risk of hypoglycemia associated with this treatment, although this remains to be clinically evaluated.…”

“…Several small clinical trials suggest that inositol supplementation could be a useful intervention or preventive measure for the insulin-related and metabolic abnormalities in PCOS, GDM and type 2 diabetes (Noventa et al 2016;Croze and Soulage 2013;Crawford et al 2015;Papaleo et al 2007;D'anna et al 2012;Gateva, Unfer, and Kamenov 2018;Colazingari et al 2013;Bizzarri and Carlomagno 2014;Unfer and Porcaro 2014;Muscogiuri et al 2016;Lubin et al 2016;Brown, Crawford Tineke, and Alsweiler 2015;Farren et al 2017;Malvasi et al 2014;Pintaudi, Di Vieste, and Bonomo 2016;D'Anna et al, 2013;Matarrelli et al 2013;Werner et al 2016;DʼAnna et al 2015;D'Anna et al, 2013;Cogram et al 2002;Cavalli et al 2011). Inositol supplementation appears to decrease glycemia and improve insulin sensitivity, but effects vary depending on the inositol isomer used, the dose and the population studied (D'anna et al 2012;Dʼ Anna et al 2015;D'Anna et al, 2013;Kim et al 2005;Santamaria et al 2012;Giordano et al 2011;Artini et al 2013;Genazzani et al 2012;Santamaria, Di Benedetto, et al 2016;Corrado et al 2011;Fraticelli et al 2018).…”